Available Technology

Breast Cancer Therapy and Potential Method for Enhancing Radiation Sensitivity via Inhibition of ß1 Integrin IB-1965

Studies with mice implanted with invasive human breast cancer cell lines show that ß1 integrin inhibitory monoclonal antibody (AIIB2) inhibits formation of tumors and significantly enhances apoptosis and decreases proliferation, and it does so in a dose-dependent manner with minimal toxicity to animals. In addition, when 3-D cultured malignant cell lines are treated with IR combined with AIIB2, the effects are enhanced by up to 50% compared to the use of IR alone. Treatment with AIIB2 resulted in only minimal apoptosis in non-malignant cell lines that have undergone differentiation in a 3 –D model, indicating that treatments focused on inhibiting ß1 activity might have little negative effect on healthy cells.
Benefits: 
In vivo studies have demonstrated the effectiveness of ß1 integrin antibody for anti-tumor therapy - In vitro studies show enhancement of radiation sensitivity - The tissue environment responds to cancer in a consistent manner, providing a reliable mechanism for treatment (compared to the variable routes taken by cells to become cancerous) - ß1 integrin inhibitory antibody had little negative effect on a non-malignant cell line - 3-D cell cultures can be used to distinguish tumors that are susceptible to the Berkeley Lab treatment
Internal Laboratory Ref #: 
IB-1965
Patent Status: 
Published Patent Application # 12/575,411 available at www.uspto.gov. Available for licensing or collaborative research
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin